EP Patent

EP2308468A1 — Novel pharmaceutical composition comprising a macrolide immunosuppressant drug

Assigned to Novaliq GmbH · Expires 2011-04-13 · 15y expired

What this patent protects

The invention provides novel pharmaceutical compositions of macrolide immunosuppressants. The compositions comprise a hydrophilic component, a lipophilic component, and an amphiphilic component Preferably, the compositions are formulated as liquid microemulsion. Furthermore, the …

USPTO Abstract

The invention provides novel pharmaceutical compositions of macrolide immunosuppressants. The compositions comprise a hydrophilic component, a lipophilic component, and an amphiphilic component Preferably, the compositions are formulated as liquid microemulsion. Furthermore, the invention provides uses of such compositions, such as for the topical treatment of inflammatory and autoimmune diseases. Methods for preparing the compositions are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP2308468A1
Jurisdiction
EP
Classification
—
Expires
2011-04-13
Drug substance claim
No
Drug product claim
No
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.